NHS study to tackle inequalities in access to genomic medicine
The initiative will examine racial and ethnic biases in the NHS Genomic Medicine Service (GMS) through national and regional assessments of health inequalities.
A recent RHO review highlighted significant gaps in health equity data for genomic services. (Representational image: iStock)
THE NHS Race and Health Observatory (RHO) and NHS England have launched an 18-month research project to address disparities faced by ethnic minority groups in accessing genomic medicine.
The initiative will examine racial and ethnic biases in the NHS Genomic Medicine Service (GMS) through national and regional assessments of health inequalities.
The study, conducted in partnership with the South East and Central & South NHS GMS Alliances and the University of Oxford, aims to identify and remove barriers that limit access to genomic services for Black, Asian, and minority ethnic communities.
A recent RHO review highlighted significant gaps in health equity data for genomic services. The underrepresentation of non-European populations in genomic databases has contributed to misdiagnoses and unequal care, risking further marginalisation of minority groups.
Launched in 2018, the NHS GMS seeks to provide equitable access to genomic testing. In 2024, an NHS Genomics Ethics, Equity, and Legal Advisory Group began working to address inequalities within the system.
Professor Habib Naqvi, chief executive of the NHS RHO, said the project aims to ensure the benefits of genomic medicine are available to all, reducing existing health disparities. Dr Veline L’Esperance of the RHO emphasised the need for collaborative efforts to dismantle barriers and create a more inclusive healthcare system.
The project will explore public health promotion strategies to build trust and engagement with diverse communities. It will also address how biases in genomic data can be mitigated to improve access for underrepresented groups.
The NHS GMS operates through seven regional centres, tasked with ensuring equitable genomic services.
Comedian and presenter Romesh Ranganathan has opened up about his long-term mental health challenges, describing how he has found effective ways to manage his wellbeing and now feels he is in “one of the best places I’ve ever been in my life”.
Speaking on BBC Radio 4’s Desert Island Discs, Ranganathan discussed experiencing suicidal thoughts in the past and the steps he has taken to improve his mental health. He also reflected on his Sri Lankan heritage, his upbringing, and the difficulties his family faced during his youth.
Managing mental health with daily routines
Ranganathan said he uses running, reading and breathing exercises to help maintain his mental wellbeing. These habits have become an important part of his routine.
“One of the things I’ve noticed when it comes to mental health is you do stuff that works… and then for some reason you just stop doing it,” he said. “You go, ‘Oh, I’ve done that every day for a week, I’m really feeling better, shall I just stop? Yeah!’ And then a few weeks later, wonder why I feel much worse.”
He described recognising when his mental health dips as “half the battle”, explaining that he is now better equipped to respond to difficult periods. “Sometimes I just go through a dark period and I know that I’ve got to do something about it,” he said.
Sharing mental health experiences responsibly
The 47-year-old broadcaster also reflected on the challenges of discussing mental health publicly, particularly when such conversations might affect others.
“You’ve got to be careful because it’s triggering [for other people],” he told presenter Lauren Laverne. “The way that I try and tackle that is to talk about it… I’m trying to destigmatise it to make the conversation normal.”
Mental health should be something people feel able to talk about openlyBBC Radio 4
However, Ranganathan acknowledged the fine line involved in public disclosures. “You do also have to be mindful of the fact that people may have been affected by that,” he said. “You don’t always get it right, but I think the rewards outweigh the risks.”
He explained that, like physical illness, mental health should be something people feel able to talk about openly. But he also emphasised the importance of being sensitive to those who may have personal experiences with suicide or depression.
Personal losses and long-term challenges
Ranganathan revealed that his struggles with mental health date back to his teenage years. He recalled particularly difficult moments during his A-levels, when his father was imprisoned for fraud, and the wider financial difficulties the family faced at the time.
“I’ve been through in my life a number of periods of suicide ideation,” he said. Despite these challenges, he said he currently feels mentally strong and positive. “As I speak now, this is running close to one of the best places I’ve ever been in my life mentally.”
His father died in 2011, but Ranganathan continues to reflect on his parents' lives and the lasting impact they’ve had on him.
Honouring his mother’s strength
During the interview, Ranganathan spoke warmly about his mother, Shanthi, and described her as “one of my heroes”. He shared how his parents moved to the UK from Sri Lanka in 1970, eight years before he was born.
While his father embraced British culture, socialising and working, Ranganathan said his mother had a very different experience. “That’s a 19-year-old girl who had kids in a foreign country,” he said. “My dad was going off to work… my mum is at home and going to the shops, but… there’s a strong argument he should’ve implemented more boundaries than he did.”
He admitted that one of his biggest regrets is “not having enough empathy or understanding” of his mother’s situation when he was growing up.
Family challenges and early life
Ranganathan recalled a difficult period when he was 12, and his father lost his job and struggled financially. “He was trying to make money in his sort of Sri Lankan Del Boy way, and it wasn’t working out,” he said. “He couldn’t keep up the mortgage repayments on their house.”
His father was later arrested and sentenced to two years in prison for fraud, an event that deeply affected Ranganathan during his teenage years.
Despite these hardships, Ranganathan eventually found success in comedy in the early 2010s and has since become a household name in the UK. He now hosts a weekend show on BBC Radio 2 and has fronted numerous popular television programmes.
Music and reflections
As part of his Desert Island Discs appearance, Ranganathan selected songs from artists including Kanye West, Eminem, and Huey Lewis and the News. His musical choices reflected different stages of his life and emotional journey.
The interview provided a rare and honest glimpse into the comedian’s personal experiences and mental health journey, offering encouragement to others who may be facing similar struggles.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
Jessie J said she was choosing to focus on the fact it was caught early and expressed gratitude
Singer Jessie J has announced she was diagnosed with early-stage breast cancer in April, sharing the news with her fans via an emotional video posted to Instagram. The 37-year-old artist revealed that she had been undergoing medical tests for the past two months while continuing to perform and release music.
“I was diagnosed with early breast cancer,” said Jessie J, whose real name is Jessica Cornish. “Cancer sucks in any form, but I’m holding on to the word ‘early’.” The Price Tag singer explained that she had been “in and out of tests” since her diagnosis, while still managing her music career and public commitments.
Balancing health and career
Jessie J said the diagnosis came shortly before the release of her latest single, No Secrets. She is scheduled to perform at Capital’s Summertime Ball at Wembley Stadium on 15 June, after which she plans to undergo surgery.
“I am going to disappear for a bit after Summertime Ball to have my surgery,” she said. “And I will come back with massive tits and more music,” she added, using humour to manage what she described as a deeply challenging experience.
Despite the serious nature of the diagnosis, Jessie J said she was choosing to focus on the fact it was caught early and expressed gratitude that it had been identified in time for treatment.
Opening up about timing and emotions
She also reflected on the timing of the diagnosis, which coincided with the promotional rollout for songs including No Secrets and Living My Best Life. Both singles were prepared in advance of her diagnosis, making the coincidence especially poignant.
“To get diagnosed with this as I’m putting out a song called No Secrets right before a song called Living My Best Life… you can’t make it up,” she said.
Jessie J explained that she needed time to process the news, and decided to speak publicly as a way of confronting the reality of her illness and to reach out to others going through similar experiences. “I just wanted to be open and share it,” she said. “Selfishly, I do not talk about it enough. I’m not processing it because I’m working so hard.”
Support from fans and friends
After her announcement, fans and fellow celebrities expressed their support in large numbers. TV presenter Gaby Roslin commented, “Sending you so much love and enormous hugs,” while others offered similar messages of encouragement and solidarity.
One follower wrote, “God is already busy healing you. You give us so much kindness. It’s time for the universe to give back some of that light.” Another said, “You are not alone. May your recovery be gentle, peaceful, and full of healing. Sending you a tight hug and all the love my heart can carry.”
Jessie J later shared on her Instagram story that she was still emotionally processing the situation. “Honestly, I need to process it and talk about it. I need a hug,” she said.
Ongoing health struggles
This is not the first time Jessie J has had to face serious health issues. She was diagnosed with a heart condition at the age of eight and suffered a minor stroke at 18. In 2020, she experienced a brief period of hearing loss, and in 2021, she went through the trauma of a miscarriage.
The singer welcomed her first child, son Sky Safir Cornish Colman, in May 2023Getty Images
In May 2023, she gave birth to her first child, a son named Sky Safir Cornish Colman, with her partner Chanan Safir Colman, a retired Danish-Israeli basketball player. Sharing her journey as a new mother has formed part of her recent online updates, as she balances her personal life with her return to the stage.
Tour still planned
Despite her diagnosis and upcoming surgery, Jessie J has not postponed or cancelled her planned tour dates. The European and UK No Secrets Tour 2025 is still scheduled to begin later this summer, with the opening show set to take place in Amsterdam.
While there may be adjustments to her schedule in the coming months, the singer has indicated she remains committed to performing and sharing new music with fans.
Spreading awareness
By sharing her diagnosis, Jessie J has once again demonstrated her openness with fans and her willingness to use her platform to raise awareness. While she acknowledged that she has not always taken time to fully process her own experiences, she said that hearing from others going through similar struggles has helped her feel less alone.
“It breaks my heart that so many people are going through so much similar and worse—that’s the bit that kills me,” she said.
With her tour on the horizon and treatment ahead, Jessie J continues to face her health challenge with strength and honesty—qualities that have long defined her music and public persona.
As Men’s Health Week 2025 (9–16 June) approaches, UK-based charity Lepra is raising awareness of hydrocele, a largely overlooked condition that significantly impacts men’s lives. A complication of lymphatic filariasis (LF), hydrocele causes fluid to accumulate in the scrotum, resulting in extreme swelling that can hinder mobility, limit income opportunities, and affect personal relationships.
Despite the availability of a simple surgical fix, many men suffer in silence due to social stigma, lack of awareness, and barriers to treatment.
A personal struggle: Arjun’s story
Arjun, 38, lives in a rural village in Odisha, India, with his wife, four children and father. As the family's main provider, he worked as a labourer until, six years ago, he began experiencing swelling and pain in his scrotum. The condition gradually worsened, leaving him unable to work effectively. Arjun endured daily discomfort, emotional distress, and increasing isolation due to embarrassment about his condition.
Post-surgery, Arjun experienced a significant improvement in his physical healthLepra
His family, unaware of the cause, worried about the financial burden of treatment. The turning point came when Arjun was screened by a Lepra programme and diagnosed with hydrocele.
Understanding hydrocele and its causes
Hydrocele is a common long-term effect of lymphatic filariasis, a neglected tropical disease transmitted by mosquitoes, usually during childhood. According to the World Health Organization (WHO), LF often remains asymptomatic for years while silently damaging the lymphatic system. As men age, this damage can manifest as chronic conditions, including lymphoedema, elephantiasis, and hydrocele.
Hydrocele can cause significant pain and immobility. Married men may struggle with intimacy, while single men often face social exclusion. In many cases, the stigma surrounding the condition leads to isolation, low self-esteem, and mental health challenges.
The simple solution: Hydrocelectomy
Hydrocele can be completely cured through hydrocelectomy, a straightforward surgical procedure with a recovery period of just two weeks. Yet access to this surgery is limited in many areas due to a shortage of trained surgeons and the stigma that prevents men from seeking help.
Following his diagnosis, Arjun received counselling to help him cope with the emotional toll of his condition. Although initially hesitant, he agreed to undergo surgery. After the operation, Arjun’s physical health improved dramatically. He regained the ability to work, restored his independence, and began reintegrating into his community.
The wider problem: Underreported and undertreated
It is estimated that up to half of men who contract LF in childhood will develop hydrocele in adulthood. In 2023 alone, WHO recorded a 258,886 increase in reported hydrocele cases globally, while only 7,380 surgeries were carried out, a stark reminder of the treatment gap.
Although hydrocelectomies are available for free in public hospitals, long waiting lists and inadequate surgical capacity prevent many from accessing timely care. In response, Lepra arranges private surgeries at a cost of just £100 for men unable to wait or travel for public treatment.
Lepra’s ongoing efforts
Lepra not only facilitates surgery but also works with local governments in India and Bangladesh to expand training for hydrocelectomy and improve access to care. The charity also runs community support groups led by trained volunteers who play a crucial role in awareness campaigns and pre-screening education.
These networks help break down stigma by informing communities about LF and the importance of early diagnosis. They also address common fears around surgery and travel, encouraging more men to come forward before the condition worsens.
About lymphatic filariasis
Lymphatic filariasis is classified by the WHO as a neglected tropical disease. It is caused by filarial parasites transmitted through mosquito bites. While infection usually begins in childhood, the consequences can appear much later, affecting the lymphatic system, kidneys, and immune response. Chronic conditions linked to LF include lymphoedema, elephantiasis, and hydrocele.
About Lepra
Lepra, originally founded in 1924 as the British Empire Leprosy Relief Association (BELRA), has been known simply as Lepra since 2008. The organisation works in India and Bangladesh, diagnosing and treating people affected by leprosy and related neglected diseases. Alongside medical care, Lepra tackles prejudice and discrimination through education, rehabilitation, and advocacy.
The charity operates under the patronage of His Majesty King Charles III and has His Royal Highness The Duke of Gloucester KG GCVO as Vice President.
To find out more or support Lepra’s work, visit:www.lepra.org.uk
Keep ReadingShow less
Participants were led to believe that 184 strangers would review a personal profile they had submitted
A new study has found that testosterone may heighten men’s sensitivity to social feedback, influencing how they perceive themselves in response to approval or disapproval. Published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, the research suggests that testosterone does not simply boost or diminish self-esteem, but changes how strongly social feedback affects an individual's sense of self-worth.
The study focuses on what psychologists call "state self-esteem," a temporary, fluctuating sense of self-worth that responds to social interactions. This is different from "trait self-esteem," which reflects a person’s more stable, long-term self-assessment. Fluctuations in state self-esteem can have significant consequences, including links to anxiety, depression, and aggression. The findings could also help explain why men with lower self-esteem might be more vulnerable to mood disorders or antisocial behaviour.
Fluctuations in state self-esteem can have significant consequencesiStock
Researchers from several institutions, including the University of Electronic Science and Technology of China and the University of Zurich, carried out the double-blind, placebo-controlled study. They recruited 120 healthy men aged 18 to 26, who were randomly assigned to receive either a testosterone gel or a placebo. After applying the gel, participants waited three hours for hormone levels to rise before taking part in a social evaluation task.
Participants were led to believe that 184 strangers would review a personal profile they had submitted and then respond with either approval (thumbs-up), disapproval (thumbs-down), or no feedback. In reality, the feedback was pre-programmed. Participants predicted how likely each rater was to approve of them and, after each round, rated how they felt about themselves, providing a real-time measure of state self-esteem.
The results showed that testosterone influenced how men formed expectations of social feedback. Those who received testosterone were more optimistic when anticipating approval from positively biased raters but more pessimistic when faced with likely disapproval. In essence, testosterone sharpened their social radar, increasing sensitivity to both praise and criticism.
More notably, testosterone amplified the emotional effects of feedback. Positive feedback led to greater boosts in self-esteem, while negative feedback caused more pronounced declines, compared to the placebo group. These patterns were assessed using computational modelling that treated self-esteem changes as a learning process, based on feedback and prediction errors.
The model revealed that testosterone did not affect the basic rate at which participants updated their self-esteem but did increase the emotional weight given to feedback. In particular, it amplified attention to both expectations and the discrepancies between expected and actual outcomes. This suggests that testosterone enhances the brain’s responsiveness to social cues, intensifying the emotional highs and lows associated with acceptance and rejection.
The findings support the idea that self-esteem functions as a “sociometer,” reflecting how accepted or rejected a person feels in their social environment. Testosterone appears to tune this sociometer, making men more emotionally responsive to social evaluations.
Men with low self-esteem are more susceptible to mental health issuesiStock
These insights could have practical implications. For instance, men with low self-esteem are more susceptible to mental health issues, and testosterone therapy is sometimes used to alleviate mood symptoms. Combining hormone treatments with positive social environments or therapies that offer regular, affirming feedback might be more effective in supporting mental well-being.
However, the study had limitations. All participants were young men, so it is unclear whether similar effects would be observed in women or in older individuals. Moreover, the researchers did not measure participants' baseline testosterone levels, which could influence how individuals respond to hormonal changes.
Another limitation lies in the study's design. Although the social evaluation task aimed to replicate real-life interactions, participants were aware they were part of an experiment, which might have affected their responses. Still, the controlled setting allowed researchers to isolate and measure the psychological processes involved.
Social evaluation task aimed to replicate real-life interactionsiStock
Future research could explore how testosterone affects social learning and self-esteem in more naturalistic settings or in clinical populations, such as those with social anxiety or depression. Additional studies could also investigate the role of other hormones and types of feedback, such as comments from peers or authority figures.
The study, titled "Testosterone Administration Increases the Computational Impact of Social Evaluation on the Updating of State Self-Esteem," was authored by Jixin Long, Junsong Lu, Yang Hu, Philippe N. Tobler, and Yin Wu. It highlights the complex role testosterone plays in shaping self-esteem and emotional sensitivity, opening new paths for understanding the hormonal underpinnings of mental health.
Keep ReadingShow less
An immunotherapy drug is given to patients before and after the surgery to improve the body's defences
A recent landmark clinical trial has revealed that a significant number of head and neck cancer patients could live longer without cancer recurrence with the help of an immunotherapy drug.
The findings of this trial are being hailed as a breakthrough for patients with these difficult-to-treat cancers, which have seen little progress in treatment over the past 20 years, according to the scientists behind the research.
Forty-five-year-old Laura Marston, who underwent surgery for advanced tongue cancer diagnosed six years ago, says she is “amazed to still be here.” She received immunotherapy both before and after her surgery.
Her diagnosis was made in 2019 after a persistent ulcer on her tongue. At the time, she was given just a 30 per cent chance of survival.
Researchers observed that immunotherapy helps train the body to defend itself and attack if the cancer returns, as demonstrated in Laura’s case.
The Institute of Cancer Research in London, together with an international team of experts, conducted the study to explore new treatment options. Laura was one of 350 patients who were given the immunotherapy drug pembrolizumab before and after surgery to prime the body’s defences.
This marks a major step forward in cancer treatment, as head and neck cancers are notoriously difficult to treat, with treatment methods having changed very little in nearly two decades.
More than half of patients diagnosed with advanced head and neck cancers have not survived beyond five years.
Laura defied the odds, recovering from a complex surgery in which part of her tongue and lymph nodes in her neck were removed. She later relearned how to speak and eat.
Other patients in the study also reported that their advanced cancers had not spread to other parts of the body.
Around 12,800 new head and neck cancer cases are diagnosed in the UK each year.
This new approach has shown promising results, doubling the average length of time patients remain cancer-free—from around 2.5 years to five years.
Additionally, patients who received pembrolizumab had a 10 per cent lower risk of their cancer returning elsewhere in the body after three years.
“We give the immune system the chance to have a good look at the tumour to generate anti-tumour immunity and then, after removal of the tumour, we continue to amplify that immune response by giving the drug continually for up to a year,” explained Professor Kevin Harrington, who led the landmark trial in the UK.